Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? – ImmunityBio (NASDAQ:IBRX), Trump Media & Technology (NASDAQ:DJT)

Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? – ImmunityBio (NASDAQ:IBRX), Trump Media & Technology (NASDAQ:DJT)


These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

  1. ImmunityBio, Inc. IBRX stock upped 49.86% after the company announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma.
  2. Stride, Inc. LRN shares rocketed 41.43% after the company reported better-than-expected first-quarter results and issued FY25 and second-quarter revenue guidance above estimates. Analysts boosted the price target on the stock.
  3. PureCycle Technologies, Inc. PCT shares jumped 32.21%.
  4. Trump Media & Technology Group Corp. DJT stock gained 31.68% last week. The stock has been volatile ahead of the upcoming U.S. election.
  5. ZEEKR Intelligent Technology ZK gained 29.31%. Several U.S.-listed Chinese stocks gained after the People’s Bank of China injected 700 billion yuan ($98.36 billion) into the banking system through its one-year medium-term lending facility, keeping the rate steady at 2.0%.
  6. IonQ, Inc. IONQ stock gained 27.52%.
  7. Herc Holdings Inc. HRI shares upped 21.76% after the company reported better-than-expected third-quarter revenue results and raised its FY24 equipment rental revenue growth outlook.
  8. TeraWulf Inc.’s WULF stock gained 18.59% amid the rise in Bitcoin’s BTC/USD price. The company also proposed to raise $425 million via convertible senior debt notes.
  9. iRhythm Technologies, Inc. IRTC stock escalated 20.76% after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes made to the Zio AT device.
  10. Celestica, Inc. CLS shares rose 19.99% after the company reported better-than-expected third-quarter results and issued Q4 revenue guidance above estimates. Several analysts raised the price target on the stock.

Also Read:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs



Source link